Volume 10, Number 8—August 2004
Research
Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000
Table 1
Antimicrobial drug coresistance in methicillin-resistant Staphylococcus aureus (MRSA) isolates and in methicillin-susceptible S. aureus (MSSA), Aberdeen Royal Infirmary, 1997–2000
Antimicrobial drug | MRSA isolates |
MSSA isolates |
Risk ratio | p value | ||
---|---|---|---|---|---|---|
No. tested for coresistance | No. resistant (%) | No. tested for coresistance | No. resistant (%) | |||
Ciprofloxacin |
1,218 |
1,195 (98.1) |
515 |
183 (35.5) |
13.4 |
< 0.0001 |
Clindamycin |
2,722 |
2,666 (97.9) |
7,715 |
956 (12.4) |
89.6 |
< 0.0001 |
Erythromycin |
2,721 |
2,669 (98.1) |
7,701 |
1,115 (14.5) |
90.0 |
< 0.0001 |
Fusidic acid |
2,736 |
36 (1.3) |
7,798 |
636 (8.2) |
0.20 |
< 0.0001 |
Gentamicin |
1,350 |
11 (0.8) |
3,276 |
44 (1.3) |
0.68 |
NSa |
Mupirocin |
2,514 |
154 (6.1) |
5,180 |
99 (1.9) |
1.92 |
< 0.0001 |
Rifampin |
1,005 |
62 (6.2) |
72 |
8 (11.1) |
0.95 |
NS |
Tetracycline |
997 |
109 (10.9) |
468 |
94 (20.1) |
0.76 |
< 0.0001 |
Trimethoprim | 1,060 | 18 (1.7) | 0 | – | – | – |
aNS, nonsignificant.